318 results on '"Sjöwall C"'
Search Results
2. POS1121 ASSESSMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY USING THE SLE DISEASE ACTIVITY SCORE (SLE-DAS): RESULTS FROM A SWEDISH TERTIARY REFERRAL CENTER
3. AB0577 LEFT VENTRICULAR DYSSYNCHRONY IN SUBJECTS WITH DIFFERENT SLE PHENOTYPES
4. POS0766 CIRCULATING SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) ASSOCIATES WITH JOINT DESTRUCTION IN JUVENILE IDIOPATHIC ARTHRITIS: A CASE-CONTROL STUDY WITH LONGITUDINAL FOLLOW-UP
5. POS1145 FACTORS ASSOCIATED WITH SURVIVAL AND DISCONTINUATION OF ANTIMALARIAL AGENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A SWEDISH LONGITUDINAL REGISTRY
6. De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab : Implications for revisiting belimumab dose
7. PO.7.162 Epidemiology of systemic lupus erythematosus in central Sweden: a population-based cohort study from the östergötland county over 14 years
8. S06.1 B cell kinetics upon therapy commencement for active extra-renal systemic lupus erythematosus in relation to development of renal flares
9. PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials
10. PO.1.20 Prognostic biomarkers of organ damage in patients with newly diagnosed SLE
11. PO.4.80 Significant correlation between adjusted mean clinical sledai over time and remission defined by the doris criteria: results from a regional Swedish cohort
12. PO.7.147 Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in patients with systemic lupus erythematosus from a Swedish tertiary referral centre
13. PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry
14. PO.3.72 Extracellular vesicles opsonized by monomeric C-reactive protein are accessible as autoantigens in systemic lupus erythematosus
15. S10.2 Interaction between HLA-DRB1*03:01 and stat4 is associated with increased risk of nephritis in systemic lupus erythematosus
16. PO.7.159 Objective measures of health-related quality of life may not adequately reflect diseaseburden in systemic lupus erythematosus
17. PO.2.45 Autoantibodies associated with systemic sclerosis (SSC) in three diseases characterized by type I interferons: a comparison between SLE, primary Sjögren’s syndrome, SSC and healthy blood donors
18. PO.8.176 Inflammation in blood and placenta in SLE pregnancies
19. PO.5.110 Plasma levels of osteopontin in SLE
20. PO.4.94 High B-cell polygenic risk is associated with dsDNA antibodies and nephritis in systemic lupus erythematosus
21. OBESITY AND TOBACCO SMOKING ARE INDEPENDENTLY ASSOCIATED WITH POOR PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A SWEDISH TERTIARY REFERRAL CENTRE
22. Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy
23. Comment on ‘Systemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challenge’: reply
24. A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity
25. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome
26. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus : a prospective study of Swedish cases with recent-onset disease
27. Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives
28. Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility
29. Resistin is Associated with Breach of Tolerance and Anti-nuclear Antibodies in Patients with Hepatobiliary Inflammation
30. ORIGINAL ARTICLE: Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögrenʼs syndrome
31. Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes
32. Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome
33. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease
34. Targeted next-generation sequencing suggests novel risk loci in juvenile onset systemic lupus erythematosus
35. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögrenʼs syndrome A antibodies
36. Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives
37. The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts
38. The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable
39. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
40. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus : associations with disease phenotypes, vascular events and damage accrual
41. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
42. A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity.
43. Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes.
44. Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome.
45. Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first‐degree relatives.
46. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual
47. FRI0347 Performance of potential definitions of remission in systemic lupus erythematosus (SLE) versus quality of life over 5 years in swedish patients with recent-onset sle
48. OP0362 Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
49. PS7:132 Smoking reduces the efficacy of belimumab in mucocutaneous lupus
50. PS4:71 Iga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.